It said Q1 2016 sales in its animal nutrition and health division showed a 4% organic growth, including 5% volume hike, compared to Q1 2015:
“This was a good result in particular considering the positive year-end effects on the timing of orders reported in Q4 2015.
“[Animal nutrition] business conditions in all major regions remained robust, with the exception of Latin America, where export conditions in Brazil were good but domestic demand was soft.
“Overall, prices showed a 1% decline versus the same period last year while currencies had a 7% negative impact on sales owing to the exposure of the business to the Brazilian real,” noted the supplements manufacturer.
DSM also reported that overall adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) for the group was up 19% to €296m.
And the company said it aims to deliver increased full-year EBITDA in line with the targets set out in its Strategy 2018: Driving Profitable Growth.
CEO, Feike Sijbesma, said: “While the macro-economic environment remains uncertain, we are confident that we will deliver in line with our medium-term goals. This will be supported by innovation, our growth initiatives and underpinned by our group-wide cost and productivity improvement programs.”